Handelsbanken Fonder AB Raises Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Handelsbanken Fonder AB boosted its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 35.6% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 34,300 shares of the company’s stock after acquiring an additional 9,000 shares during the period. Handelsbanken Fonder AB’s holdings in IDEAYA Biosciences were worth $562,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Geode Capital Management LLC boosted its position in shares of IDEAYA Biosciences by 2.2% in the 4th quarter. Geode Capital Management LLC now owns 1,988,681 shares of the company’s stock worth $51,121,000 after purchasing an additional 43,226 shares in the last quarter. State of New Jersey Common Pension Fund D raised its stake in IDEAYA Biosciences by 62.9% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 81,174 shares of the company’s stock valued at $2,086,000 after buying an additional 31,335 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in IDEAYA Biosciences by 3.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 712,811 shares of the company’s stock worth $18,319,000 after acquiring an additional 23,738 shares in the last quarter. Norges Bank purchased a new stake in shares of IDEAYA Biosciences during the fourth quarter worth about $13,385,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of IDEAYA Biosciences during the fourth quarter worth about $383,000. 98.29% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, JPMorgan Chase & Co. lifted their target price on shares of IDEAYA Biosciences from $63.00 to $66.00 and gave the stock an “overweight” rating in a research note on Thursday, May 22nd. Two investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, IDEAYA Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $54.27.

IDEAYA Biosciences Price Performance

NASDAQ:IDYA opened at $22.18 on Monday. The company’s fifty day moving average price is $18.94 and its 200-day moving average price is $21.07. IDEAYA Biosciences, Inc. has a 1-year low of $13.45 and a 1-year high of $44.42. The firm has a market capitalization of $1.94 billion, a P/E ratio of -6.72 and a beta of 0.04.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same period in the prior year, the business earned ($0.53) earnings per share. Equities analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.